Category: Insulin

sanofi-logo

FDA Approves Toujeo, Sanofi’s New Long Acting Insulin 

The U.S. Food and Drug Administration (FDA) approved Sanofi’s new once daily long acting insulin, Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL) for treatment of adults living with type 1 and type 2 diabetes. Toujeo will be available in the Toujeo SoloSTAR, a disposable prefilled pen which contains 450 units of Toujeo and requires one third of the injection volume to deliver the same number of insulin units as compared to the Lantus SoloSTAR.
0 Shares
New Diabetes Products 2015 2

7 New Diabetes Products to Look for in 2015

J&J Animas finally received US FDA approval of their Animas Vibe Dexcom-integrated insulin pump that has been available in Europe since 2011 and will start shipping in January 2015. Another player in the CGMS business, Abbott Diabetes, received the CE Mark for their new FreeStyle Libre Flash Glucose Monitoring system in 2014.
0 Shares
Novo Nordisk Logo

Novo Nordisk’s Type 2 Diabetes Drug Xultophy Approved in the EU

Novo Nordisk has been granted marketing authorization by the European Commission for a new injectable, Xultophy, for the treatment of Type 2 diabetes in adults. Xultophy is the brand name for IDegLira, the first once-daily single injection combination of insulin degludec (Tresiba) and liraglutide (Victoza).
0 Shares
Novo Nordisk Logo

Novo Nordisk’s Ryzodeg Does The Job With Fewer Injections

Data presented today at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD) show that Ryzodeg (insulin degludec/insulin aspart) administered twice daily, provides successful glycaemic control with fewer injections than a basal-bolus regimen for type 2 diabetes patients. Ryzodeg is a combination of two distinct insulin analogues , insulin degludec (Tresiba) and insulin aspart (Novolog) in the ratio of 70% and 30%, making it the first combination of a basal insulin with an ultra-long duration of action and a well-established mealtime insulin in one pen for people with type 2 diabetes.
0 Shares
Novo Nordisk Logo

Novo Nordisk’s Tresiba Safe for Children with Type 1 Diabetes

Today, at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), Novo Nordisk announced new data from the BEGIN® YOUNG 1 trial. The study investigates once-daily Tresiba (insulin degludec) versus basal insulin Levemir (detemir), both in combination with bolus insulin Novolog (aspart) in a 52-week trial in children and adolescents with type 1 diabetes. This trial is the first to look into the long-term safety of Tresiba in children and adolescents (from age 1 to less than 18 years) and the results show that Tresiba in combination with Novolog (Novorapid) effectively improved long-term glycemic control.
0 Shares
Lilly - Boehringer - logo

Lilly and Boehringer Ingelheim’s New Insulin Glargine Approved in the EU

The European Commission has granted marketing authorisation for Eli Lilly and Company and Boehringer Ingelheim's insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and above. The European Commission has granted marketing authorisation for Eli Lilly and Company and Boehringer Ingelheim's insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and above.
0 Shares